BSX · News · 20261102N
Net Income and EPS Performance
BOSTON SCIENTIFIC CORP · 2026-11-02 · Importance 47 · Surprise 48 · No source text
Boston Scientific’s third-quarter 2026 net income declined to $580 million from $755 million in Q3 2025, a decrease of approximately 23%. A separate Q3 summary reported net income of $582 million, down 22.9%, and diluted EPS of $0.40, down 21.6%. The reports attributed the profit decline primarily to an August cybersecurity incident that disrupted manufacturing and order fulfillment, as well as increased litigation-related charges.
Key facts
- Boston Scientific Q3 2026 net income declined 22.9% to $582 million. source
- Boston Scientific Q3 2026 diluted EPS fell 21.6% to $0.4. source
- Boston Scientific Q3 2026 net income was $580 million, compared with $755 million in the prior year. source
- Boston Scientific's Q3 2026 performance was impacted by increased litigation-related charges. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | realized | -3.2% | Boston Scientific Q3 2026 net income declined 22.9% to $582 million. |